Malignant B-cell neoplasms research hub

Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasms

This early-stage study is looking at a new treatment called STAb-T19 cells for certain blood cancers. Researchers want to see if these specially modified cells are safe when given to people for the first time. The aim is to fight cancer by using the body's own immune system.